Drugs / PD-1 antibody expressing mesothelin specific CAR-T cells
PD-1 antibody expressing mesothelin specific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03030001 | Feb 2017 → Dec 2018 | cancer | Ningbo Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1 antibody expressing mesothelin specific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03030001 ↗ |
| Modality | Cell therapy | “autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor” NCT03030001 ↗ |
| Route | Intravenous | “cells will be infused intravenously (i.v.)” NCT03030001 ↗ |